What CJC-1295 is
CJC-1295 is a synthetic version of growth hormone-releasing hormone (GHRH), the signal the brain uses to tell the pituitary gland to release growth hormone. It was modified to resist breakdown in the blood.
It is sold two ways. CJC-1295 with DAC carries an add-on that binds to albumin in the blood and stretches its activity to days. CJC-1295 without DAC, also called Mod GRF 1-29, lasts a short time. The names get mixed up constantly, so read the label and the certificate of analysis closely.
Tesamorelin (Egrifta) is a different GHRH analog that is FDA-approved for a specific condition in people with HIV. It is not CJC-1295.
Regulatory status in 2026
CJC-1295 is not an approved drug and is not on the list of substances pharmacies may compound from. It was not part of the 2026 peptide changes that got most of the headlines.
A company tests the DAC version in early human studies. Development does not continue to approval.
FDA's Pharmacy Compounding Advisory Committee votes against adding CJC-1295 to the compounding list.
CJC-1295 is not among the peptides removed from Category 2 in April or reviewed in July.
Not approved, not compoundable, and prohibited at all times under WADA class S2 as a growth hormone-releasing factor.
Regulatory status can change. Check the sources linked at the bottom of this page before relying on anything here.
Claims vs. what the research shows
CJC-1295 is one of the few peptides in this group with published human data. That data shows it changes hormone levels. It does not show the outcomes it is marketed for.
Raises growth hormone and IGF-1.
Shown in small studies of healthy adults with the DAC version. This is the best-supported claim.
Strong human evidenceBuilds muscle and burns fat.
Not shown. Raising hormone levels is not the same as producing those results, and no trials measured them.
Insufficient dataSlows aging.
No human evidence.
Insufficient dataStorage and stability
Peptides break down with heat, light, moisture, and repeated freezing and thawing. Degraded product is one common reason two vials of the "same" peptide behave differently. These are general peptide handling practices. Your supplier's certificate of analysis or label takes priority.
Sealed powder (lyophilized)
- Refrigerate at 36 to 46°F (2 to 8°C) for routine storage.
- Freezer is generally used for long-term storage.
- Keep in its original sealed vial, away from light.
- Let a cold vial reach room temperature before opening to limit condensation.
After reconstitution
- Keep refrigerated. Do not freeze.
- Protect from light. Clear glass lets it through.
- Opened multi-dose bacteriostatic water is typically discarded 28 days after first puncture.
- Log the mix date so you know the vial's age at a glance.
Light exposure is easy to overlook in a fridge door that opens dozens of times a day. VIALTIGHT is building stackable cases that block light from every side. See vialtight.com for updates.
Reconstitution math
Concentration is just the amount of peptide divided by the volume of water added. On a U-100 insulin syringe, 100 units equals 1 mL, so each unit is 0.01 mL. Enter what is on your vial label and what you added to see the concentration.
This shows concentration only. It is not a dosing recommendation. VialTracker runs this math for every vial you log and keeps it with the vial's history.
Safety flags
Product quality is unverified. Gray-market vials have been found underdosed, mislabeled, or contaminated. A certificate of analysis from the seller is not the same as independent testing.
DAC and no-DAC get swapped. They behave very differently in the body. A mislabeled vial is not a minor error.
Long-term hormone effects are unknown. Keeping IGF-1 elevated for long periods has not been studied with this compound. Side effects reported in early studies included flushing and injection site reactions.
Tested athletes. Prohibited at all times under WADA class S2.
FAQ
What is the difference between CJC-1295 and Mod GRF 1-29?
Mod GRF 1-29 is CJC-1295 without DAC. It is short-acting. CJC-1295 with DAC is long-acting. They are not interchangeable.
Can a compounding pharmacy make CJC-1295?
Not legally under current federal rules. FDA's advisory committee voted against adding it to the compounding list in 2024.
Is CJC-1295 the same as tesamorelin?
No. Tesamorelin is a separate, FDA-approved GHRH analog with its own label.
Does VialTracker tell me what to take?
No. VialTracker organizes the information you enter and runs the math. It does not recommend doses, products, or protocols.